Diabetes in pregnancy: Management of diabetes and its complications from pre-conception to the postnatal period
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/cg63
Changes after publication
October 2012: minor maintenance
June 2012 : minor maintenance
July 2008: Since publication, the information on the therapeutic indications, contraindications and use in pregnancy and lactation of drugs used in diabetes management and retinal assessment (specifically insulins, the oral hypoglycaemic agents metformin and glibenclamide, and tropicamide) has been corrected to follow the relevant summaries of product characteristics (SPCs) (July 2008). Changes have been made to the NICE guideline, the full guideline and the quick reference guide.
'The recommendation on the use of the rapid-acting insulin analogues aspart and lispro in pregnant women with diabetes (this is recommendation 188.8.131.52 in the NICE guideline) is now as follows:
Healthcare professionals should be aware that data from clinical trials and other sources do not suggest that the rapid-acting insulin analogues (aspart and lispro) adversely affect the pregnancy or the health of the fetus or newborn baby.
The electronic versions of the guideline on this website all contain the correct information on drugs used in diabetes management and retinal assessment. Hard copies of the corrected quick reference guide are being mailed to the NHS.
The Information for the public does not give all details of the information healthcare professionals need to consider when prescribing insulin and other drugs used to manage diabetes or for retinal assessment in women who are pregnant or breastfeeding. Therefore it did not require any changes to reflect the reissued guideline on diabetes in pregnancy and has not been reissued.